Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2011

01-10-2011

Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome

Authors: Clothilde Martel, Guillaume Gondran, David Launay, Fabrice Lalloué, Sylvain Palat, Marc Lambert, Kim Ly, Veronique Loustaud-Ratti, Holly Bezanahary, Eric Hachulla, Marie Odile Jauberteau, Elisabeth Vidal, Pierre Yves Hatron, Anne Laure Fauchais

Published in: Journal of Clinical Immunology | Issue 5/2011

Login to get access

Abstract

Background

The aim of this paper was to study the evolution of primary Sjögren’s syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS (n = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months).

Methods

This is a retrospective cohort study.

Results

Two hundred twelve patients were Sjögren’s syndrome A (SSA) positive, and 131 were both SSA and Sjögren’s syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren’s syndrome A (anti-SSA), anti-Sjögren’s syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death.

Conclusion

The subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.
Literature
1.
go back to reference Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12(5):391–8.PubMedCrossRef Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12(5):391–8.PubMedCrossRef
2.
go back to reference Alexander E, Arnett F, Provost T. Sjögren’s syndrome: association of anti-SSa antibodies with vasculitis, immunologic abnormalities and serologic hyperactivity. Ann Med Int. 1983;98:155–9. Alexander E, Arnett F, Provost T. Sjögren’s syndrome: association of anti-SSa antibodies with vasculitis, immunologic abnormalities and serologic hyperactivity. Ann Med Int. 1983;98:155–9.
3.
go back to reference Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjögren’s syndrome. Clin Exp Rheumatol. 1989;7(2):185–90.PubMed Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjögren’s syndrome. Clin Exp Rheumatol. 1989;7(2):185–90.PubMed
4.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European study group on classification criteria for Sjögren’s syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European study group on classification criteria for Sjögren’s syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.PubMedCrossRef
5.
go back to reference Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9.CrossRef Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9.CrossRef
6.
go back to reference Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46(3):741–7.PubMedCrossRef Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46(3):741–7.PubMedCrossRef
7.
go back to reference Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164–72.CrossRef Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164–72.CrossRef
8.
go back to reference Van Bijsterveld O. Diagnosis and differential diagnosis of keratoconjunctivitis sicca associated with tear gland degeneration. Clin Exp Rheumatol. 1990;8(5):3–6.PubMed Van Bijsterveld O. Diagnosis and differential diagnosis of keratoconjunctivitis sicca associated with tear gland degeneration. Clin Exp Rheumatol. 1990;8(5):3–6.PubMed
9.
go back to reference Schall G, Andferson L, Wolf R, Herdt J, Tarpley T, Cummings N, et al. Xerostomia in Sjögren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA. 1971;216:2109–16.PubMedCrossRef Schall G, Andferson L, Wolf R, Herdt J, Tarpley T, Cummings N, et al. Xerostomia in Sjögren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA. 1971;216:2109–16.PubMedCrossRef
10.
11.
go back to reference Asmussen K, Andersen V, Bendixen G, Schiodt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996;239(6):475–82.PubMedCrossRef Asmussen K, Andersen V, Bendixen G, Schiodt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996;239(6):475–82.PubMedCrossRef
12.
go back to reference Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93.CrossRef Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93.CrossRef
13.
go back to reference Muller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjögren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol. 1989;18(1):29–31.PubMedCrossRef Muller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjögren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol. 1989;18(1):29–31.PubMedCrossRef
14.
go back to reference Fauchais A, Lambert M, Dubucquoi S, Hachulla E, Pasturel U, Queyrel V, et al. Inaugural Raynaud’s phenomemon is associated with a multisystemic involvement during follow up in primary Sjögren syndrome—A report of 162 patients. Int J Angiology. 2004;13(2):1061–711. Fauchais A, Lambert M, Dubucquoi S, Hachulla E, Pasturel U, Queyrel V, et al. Inaugural Raynaud’s phenomemon is associated with a multisystemic involvement during follow up in primary Sjögren syndrome—A report of 162 patients. Int J Angiology. 2004;13(2):1061–711.
15.
go back to reference Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80.CrossRef Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80.CrossRef
16.
go back to reference Ramos M, Cervera R, Garcia-Carrasco M, Miret C, Munoz FJ, Espinosa G, et al. Primary Sjögren’s syndrome: clinical and immunologic study of 80 patients. Med Clin (Barc). 1997;108(17):652–7. Ramos M, Cervera R, Garcia-Carrasco M, Miret C, Munoz FJ, Espinosa G, et al. Primary Sjögren’s syndrome: clinical and immunologic study of 80 patients. Med Clin (Barc). 1997;108(17):652–7.
17.
go back to reference Ramos-Casals M, Font J, Garcia-Carrasco M, Brito MP, Rosas J, Calvo-Alen J, et al. Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–92.CrossRef Ramos-Casals M, Font J, Garcia-Carrasco M, Brito MP, Rosas J, Calvo-Alen J, et al. Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–92.CrossRef
18.
go back to reference Ramos-Casals M, Anaya JM, Garcia-Carrasco M, Rosas J, Bove A, Claver G, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83(2):96–106.CrossRef Ramos-Casals M, Anaya JM, Garcia-Carrasco M, Rosas J, Bove A, Claver G, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83(2):96–106.CrossRef
19.
go back to reference Leone J, Pennaforte JL, Hamon R, Cleenewerck N, Vallerand H, Detree F, et al. Pulmonary manifestations of primary Gougerot-Sjögren syndrome. Apropos of 8 cases in a series of 35 patients. Rev Med Interne. 1996;17(4):291–9.PubMedCrossRef Leone J, Pennaforte JL, Hamon R, Cleenewerck N, Vallerand H, Detree F, et al. Pulmonary manifestations of primary Gougerot-Sjögren syndrome. Apropos of 8 cases in a series of 35 patients. Rev Med Interne. 1996;17(4):291–9.PubMedCrossRef
20.
go back to reference Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren’s syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol. 1995;24(6):342–5.PubMedCrossRef Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren’s syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol. 1995;24(6):342–5.PubMedCrossRef
21.
go back to reference Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996;39(5):767–72.PubMedCrossRef Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996;39(5):767–72.PubMedCrossRef
22.
go back to reference Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803.PubMedCrossRef Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803.PubMedCrossRef
23.
go back to reference Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74.PubMedCrossRef Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74.PubMedCrossRef
24.
go back to reference Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–62.CrossRef Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–62.CrossRef
25.
go back to reference Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjögren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol. 2000;123(1):46–57.PubMedCrossRef Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjögren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol. 2000;123(1):46–57.PubMedCrossRef
26.
go back to reference Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64(7):1050–5.PubMedCrossRef Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64(7):1050–5.PubMedCrossRef
27.
go back to reference Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, et al. Primary Sjögren’s syndrome in north east England–a longitudinal study. Br J Rheumatol. 1991;30(6):437–42.PubMedCrossRef Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, et al. Primary Sjögren’s syndrome in north east England–a longitudinal study. Br J Rheumatol. 1991;30(6):437–42.PubMedCrossRef
28.
go back to reference Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38(3):245–53.CrossRef Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38(3):245–53.CrossRef
29.
go back to reference Cho CS, Park SH, Min JK, Lee SH, Kim HY. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med. 1997;12(2):176–81.PubMed Cho CS, Park SH, Min JK, Lee SH, Kim HY. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med. 1997;12(2):176–81.PubMed
30.
go back to reference Ichigawa Y, Takada M, Shimizu H, Uchiyama M, Motiushi J, Morita K. Clinical and immunological features of 106 patients with primary Sjögren’s syndrome: comparison of patients with and without other specific autoimmune disease or anti-SSa antibodies. Jap J of Rheum. 1993;4(3):153–64. Ichigawa Y, Takada M, Shimizu H, Uchiyama M, Motiushi J, Morita K. Clinical and immunological features of 106 patients with primary Sjögren’s syndrome: comparison of patients with and without other specific autoimmune disease or anti-SSa antibodies. Jap J of Rheum. 1993;4(3):153–64.
31.
go back to reference Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999;28(4):227–32.PubMedCrossRef Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999;28(4):227–32.PubMedCrossRef
32.
go back to reference Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202–6.PubMedCrossRef Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202–6.PubMedCrossRef
Metadata
Title
Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome
Authors
Clothilde Martel
Guillaume Gondran
David Launay
Fabrice Lalloué
Sylvain Palat
Marc Lambert
Kim Ly
Veronique Loustaud-Ratti
Holly Bezanahary
Eric Hachulla
Marie Odile Jauberteau
Elisabeth Vidal
Pierre Yves Hatron
Anne Laure Fauchais
Publication date
01-10-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-011-9553-3

Other articles of this Issue 5/2011

Journal of Clinical Immunology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.